Eledon Pharmaceuticals, Inc.
ELDN- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001404281
No open-market purchases or sales by Eledon Pharmaceuticals, Inc. insiders were filed in the last 90 days; 161 institutions reported holding it in 13F filings for Q2 2026, worth $184.6M in total; no superinvestor holds it.
Q4 2022 vs. Q3 2022
How the institutions holding Eledon Pharmaceuticals, Inc. changed between Q3 2022 and Q4 2022.
All holders in Q4 2022All holders in Q3 2022
| Measure | Q3 2022 | Q4 2022 | Change |
|---|---|---|---|
| Holders | 31 | 28 | −3 |
| Shares | 6.27M | 6.25M | −17.1K (−0.3%) |
| Value | $17.3M | $14.4M | −$2.92M (−16.9%) |
New holders (2)
Institutions that held Eledon Pharmaceuticals, Inc. at the end of Q4 2022 but not at the end of Q3 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| SVB Financial Group | 40,613 | $93.1K | 0.25% |
| Bank of America Corp | 14 | $32 | 0.00% |
Sold out (5)
Institutions that held Eledon Pharmaceuticals, Inc. at the end of Q3 2022 and filed for Q4 2022 without it.
| Institution | Shares, Q3 2022 | Value, Q3 2022 |
|---|---|---|
| Point72 Asset Management, L.P. | 375,000 | $1.03M |
| Federated Hermes, Inc. | 339 | $1.00K |
| Spire Wealth Management | 500 | $1.00K |
| Royal Bank of Canada | 38 | $0 |
| Cubist Systematic Strategies, LLC | 35 | $0 |